PROCYON CORP
PROCYON CORP (PCYN): 3 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.40 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for PROCYON CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6M
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| advantagen | Approved |
| amerigel hydrogel wound dressing | Approved |
| helix3 bioactive collagen | Approved |
Frequently asked questions
How many drug candidates are in PROCYON CORP's pipeline?
PROCYON CORP (PCYN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROCYON CORP's lead drug candidate?
PROCYON CORP's most advanced tracked candidate is advantagen (Approved) for wound closure and surgical site infection.
What is PROCYON CORP's market capitalization?
PROCYON CORP's market capitalization is approximately $1.6M.
Who is the CEO of PROCYON CORP?
Mr. Justice W. Anderson is the chief executive officer of PROCYON CORP (PCYN).
Get the full picture on PROCYON CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.